References

177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, Phase II study

10.1200/jco-25-01553 · 2025 · External reference

Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer

10.1056/nejmoa2403365 · 2024 · External reference

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

10.1016/s0140-6736(20)30314-7 · 2020 · External reference

68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy

10.1016/j.ajur.2020.02.001 · 2021 · External reference

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

10.1016/s1470-2045(24)00326-7 · 2024 · External reference

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

10.1016/s1470-2045(25)00339-0 · 2025 · External reference

The co-IMPACT consortium: integrating prostate-specific membrane antigen positron emission tomography and radiotherapy in prostate cancer care

10.1016/j.eururo.2025.01.003 · 2025 · External reference

Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: a Phase 2 randomized clinical trial

10.1001/jamaoncol.2025.3746 · 2025 · External reference

Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation

10.1186/s13063-026-09709-0 · 2026 · External reference

The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer

10.1002/cncr.23139 · 2008 · External reference

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

10.1186/1741-7015-8-18 · 2010 · External reference

PSMA-PET/CT-guided intensification of radiation therapy for prostate cancer (PSMAgRT): findings of detection rate, effect on cancer management, and early toxicity from a Phase 2 randomized controlled trial

10.1016/j.ijrobp.2022.12.055 · 2023 · External reference

Simplified and robust one‐step radiosynthesis of [18F]DCFPyL via direct radiofluorination and cartridge‐based purification

10.1002/jlcr.3632 · 2018 · External reference

PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial

10.1186/s12885-022-09283-z · 2022 · External reference

A systematic review on the role of imaging in early recurrent prostate cancer

10.1016/j.euo.2018.09.010 · 2019 · External reference

PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer

10.1007/s11307-016-0957-6 · 2016 · External reference

Aging of the progenitor cells that initiate prostate cancer

10.1016/j.canlet.2021.05.014 · 2021 · External reference